This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
News|Articles|August 5, 2024
Roundup: Novel Drug Approvals in 2024
In the first half of 2024, the FDA approved 23 novel drugs for conditions including alopecia areata, Alzheimer disease, small cell lung cancer, bladder cancer, and more.
Advertisement
Advertisement
In the first half of 2024, the FDA has approved 23 novel drugs, including indications for alopecia areata, Alzheimer disease, small cell lung cancer, bladder cancer, and more. In the first 6 months alone, there were 20 novel approvals.
Related to this article
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The approval is supported by data from the phase 3 FINE-ONE clinical trial.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Advertisement
Advertisement